肽通与Evotec建立战略合作伙伴关系，选择性靶向内在无序蛋白（IDPs），并大规模推进小分子治疗药物的发展-动脉网

Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale

CISION 等信源发布 2025-05-08 19:00



可切换为仅中文







The partnership will focus on high-value IDP targets, including transcription factors, kinases and other disordered proteins with strong biological and clinical therapeutic hypotheses

该合作将专注于高价值的IDP靶点，包括转录因子、激酶和其他具有强烈生物学和临床治疗假设的无序蛋白。

Evotec's depth of assay expertise, well-curated medicinal chemistry-ready libraries, and drug discovery capability will enable rapid engagement of several high value targets

Evotec在检测方面的深厚专业知识、精心策划的药物化学准备库以及药物发现能力将能够快速锁定多个高价值靶点。

The collaboration will accelerate Peptone's IDP target selection and validation processes for the development of novel therapeutic solutions

该合作将加速Peptone用于开发新型治疗方案的IDP靶点选择和验证过程。

LONDON

伦敦

and BELLINZONA,

和贝林佐纳，

Switzerland

瑞士

，

May 8, 2025

2025年5月8日

/PRNewswire/ -- Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases, today announced a partnership with Evotec to accelerate and scale the creation of small molecule IDP-targeted treatments across diverse therapeutic areas. Through the collaboration, Peptone will harness Evotec's drug discovery toolbox — encompassing deep domain expertise in oncology and immunology, extensive assay development know-how, and state-of-the-art screening capabilities — to seamlessly integrate with its pioneering, physics-based approach to understanding IDP structural dynamics..

/PRNewswire/ -- Peptone是一家开发针对内在无序蛋白（IDPs）的新型疗法以治疗疾病的生物技术公司，今天宣布与Evotec达成合作，加速并扩大针对多种治疗领域的小分子IDP靶向治疗药物的研发。通过此次合作，Peptone将利用Evotec的药物发现工具箱——包括在肿瘤学和免疫学领域的深厚专业知识、广泛的检测开发技术以及最先进的筛选能力——与其基于物理学的开创性方法无缝结合，深入理解IDP结构动态。

'Our novel strategy to industrialize Peptone's proprietary ultra-fast Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) platform and Evotec's cutting-edge medicinal chemistry expertise is crucial for transforming our unique structural insights into viable therapeutic approaches,' said Dr.

“我们新颖的战略是将Peptone专有的超快速氢氘交换质谱（HDX-MS）平台工业化，并结合Evotec前沿的药物化学专业知识，这对将我们独特的结构洞见转化为可行的治疗方案至关重要，”博士说道。

Kamil Tamiola

卡米尔·塔米奥拉

, physicist and Chief Executive Officer of Peptone. 'Evotec's commitment to innovation positions them as an optimal partner in addressing the intricacies of drug design for IDPs and facilitating the introduction of effective therapies to the market.'

Peptone的物理学家兼首席执行官表示：“Evotec对创新的承诺使他们成为解决IDPs药物设计复杂问题的最佳合作伙伴，并有助于将有效疗法推向市场。”

While traditional drug design is limited to fixed protein structures, Peptone's bespoke HDX-MS platform reveals novel structural insights for dynamic, disordered proteins regardless of protein size or complexity, identifying IDP pockets for targeting that have remained undetectable to traditional structural biochemistry methodologies and AI approaches.

传统药物设计受限于固定的蛋白质结构，而 Peptone 定制的 HDX-MS 平台能够揭示动态无序蛋白质的新结构见解，无论蛋白质的大小或复杂性如何，并识别出传统结构生物化学方法和人工智能方法无法检测到的 IDP 口袋以供靶向。

By integrating breakthrough science with AI-powered platforms and advanced technologies, Evotec possesses the capabilities to create life-changing medicines at speed and with precision. The collaboration seeks to eliminate the traditional bottleneck in early target selection and allows for the rapid, scalable generation of tractable chemical matter, designed to target a range of IDPs with Peptone-identified pockets.

通过将突破性科学与人工智能平台和先进技术相结合，Evotec具备了快速且精准地开发生命改变药物的能力。该合作旨在消除早期靶点选择中的传统瓶颈，实现针对Peptone识别的口袋范围内的IDP（内在无序蛋白）快速、可扩展的易处理化合物生成。

Selection of programs will focus on pockets that have been successfully drugged based on in vitro evidence of target modulation..

程序的选择将侧重于那些基于体外靶点调节证据已成功药物作用的领域。

'We are thrilled to enter this partnership with Peptone as it unlocks the opportunity to advance novel therapies against previously intractable targets that are known to play important role(s) in cancer, autoimmunity, and beyond,' said Dr. Cord Dohrmann, Chief Scientific Officer of Evotec. 'We believe the integration of Evotec's comprehensive drug discovery platform with Peptone's technology for mapping intrinsically disordered proteins as druggable targets will enable development of viable drug candidates with unprecedented speed and efficiency, at scale, without sacrificing quality.'.

“我们很高兴与Peptone达成这一合作，因为它为我们提供了针对过去难以解决的、在癌症、自身免疫等领域中已知具有重要作用的靶点推进新型疗法的机会，”Evotec首席科学官Cord Dohrmann博士表示。“我们认为，将Evotec全面的药物发现平台与Peptone用于绘制内在无序蛋白作为可成药靶点的技术相结合，将以空前的速度和效率大规模开发出可行的候选药物，同时不会牺牲质量。”

About Peptone

关于Peptone

Peptone is a biotechnology company developing novel first-in-class small molecule therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases through a pioneering experimental approach that starts with studying the structural dynamics of IDPs. Peptone's technology accurately translates bespoke experimental data into dynamic models of disordered proteins regardless of protein size or complexity with the necessary speed and insights to design therapeutics capable of affecting IDP function.

Peptone是一家生物技术公司，致力于开发针对内在无序蛋白（IDPs）的新型一流小分子治疗药物，通过一种开创性的实验方法治疗疾病，该方法从研究IDPs的结构动力学入手。Peptone的技术能够快速准确地将定制的实验数据转化为无序蛋白质的动态模型，无论蛋白质的大小或复杂性如何，并提供设计影响IDP功能的治疗药物所需的速度和见解。

The company's initial focus is on oncology targets areas of highly unmet need with strong disease hypotheses and biological validation. For more information about Peptone, visit .

公司最初的重点是肿瘤学领域，这些领域具有高度未满足的需求，并且有强有力疾病假设和生物学验证。有关Peptone的更多信息，请访问。

https://peptone.io

。

About Evotec

关于Evotec

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-powered platforms and advanced technologies, we accelerate the creation of life-changing medicines — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, and cell therapies, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling..

Evotec是一家生命科学公司，致力于开创药物发现与开发的未来。通过将突破性科学与人工智能平台及先进技术相结合，我们加速了改变生命的药物的创造——更快、更智能、更精确。我们的专业知识涵盖小分子、生物制品和细胞疗法，并依托专有平台支持，如分子患者数据库、泛组学和基于iPSC的疾病模型。

With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility..

通过灵活的合作伙伴模式，根据客户需求量身定制，我们与所有前20大制药公司、800多家生物技术公司、学术机构和医疗保健利益相关者合作。我们的服务范围涵盖从独立服务到完全集成的研发项目和长期战略合作关系，将科学卓越性与运营敏捷性相结合。

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

通过Just – Evotec生物制剂，我们重新定义了生物制剂的开发和生产，以提高其可及性和可负担性。

With a strong portfolio of over 100 co-owned and proprietary R&D projects, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

拥有超过100个共同拥有和自主知识产权的研发项目，我们专注于包括肿瘤学、心血管和代谢疾病、神经学以及免疫学在内的关键治疗领域。

Evotec's global team of more than 4,800 experts operates from sites in

药明康德在全球的团队由超过4800名专家组成，分布于多个地点。

Europe

欧洲

and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at

和美国提供互补的技术和服务，作为协同卓越中心。了解更多，请访问

www.evotec.com

and follow us on

关注我们

领英

and X/Twitter